{"changes":[],"country":"NL","description":"NewAmsterdam Pharma develops obicetrapib, an oral CETP inhibitor for cardiovascular disease in patients who cannot reach LDL targets on statins alone. Patients with familial hypercholesterolemia and atherosclerotic disease are the target population. The company spun out the program from Amgen and is pursuing Phase 3 clinical readouts.","domain":"newamsterdampharma.com","employees":null,"founded":2019,"fundingTotalQuarantined":false,"githubOrg":null,"githubStars":null,"industry":"bio","investors":[],"lat":52.307009,"lng":5.141733,"location":"Amsterdam","name":"NewAmsterdamPharma","rounds":[{"amountQuarantined":false,"amountUsd":453000000,"currency":"USD","date":"2024-12-01","investors":[],"leadInvestor":null,"source":{"fact":"round","publisher":"sifted","retrievedAt":"2026-06-05","status":"attributed","url":null},"status":"attributed","type":"seed","url":null}],"slug":"newamsterdampharma-com","sources":[{"fact":"round","publisher":"sifted","retrievedAt":"2026-06-05","status":"attributed","url":null},{"fact":"existence","publisher":"newamsterdampharma.com","retrievedAt":"2026-06-05","status":"self-reported","url":"https://newamsterdampharma.com"},{"fact":"description","publisher":"newamsterdampharma.com","retrievedAt":"2026-06-05","status":"self-reported","url":"https://newamsterdampharma.com"}],"stage":"series-b+","techStack":["adobe fonts","cloudflare","cloudflare bot management","google tag manager","http/3","jquery 3.7.1","mysql","php","typekit","wordpress","wp engine","yoast seo 27.7"],"totalRaisedUsd":453000000,"updatedAt":"2026-06-05"}